Blog & Resources Camargo Blog November 5th, 2007

505(b)(2)—Part 2: The Assessment: Competitive Product(s) Review

We investigate major factors that influence the potential clinical evidence required and the likelihood of a product’s acceptance in the market. Having established a working draft of our labeled indication(s), we look at the therapeutic category. What drugs have been used, are currently used and what drugs are being studied for eventual marketing?

This comparative review serves two major purposes. First, we are determining the clinical threshold to be met by our new product and second, what is the likely market acceptance. Clearly, the two objectives are interrelated. By looking at what clinical studies are being conducted we can see the design and the primary and secondary endpoints. Not only will FDA impose at least some of the learning’s from these competitor studies on our clinical program but we learn what evidence will be used by the marketplace (physicians, formularies) to select the products in the near future.

Thus, we provide an assessment of the existence of an unmet medical need and the ability of the proposed drug to compete with existing and pipeline agents. In summary, we provide:

  • Insight into the market
  • Pipeline overview
    • Products in development
    • Clinical trials in progress (i.e, CenterWatch)
  • Competitor’s Strategy
    • Pricing
    • Patents
    • Diversification
    • In-licensing

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights